Ask about this productRelated genes to: BCAP31 antibody
- Gene:
- BCAP31 NIH gene
- Name:
- B cell receptor associated protein 31
- Previous symbol:
- -
- Synonyms:
- DXS1357E, BAP31, 6C6-Ag, CDM
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-22
- Date modifiied:
- 2017-12-06
Related products to: BCAP31 antibody
Related articles to: BCAP31 antibody
- - Source: PubMed
Publication date: 2026/04/24
Khonsari Yasamin NasiriHabibi RezaAlami FatemehMustafa Rana MahmoudVarkiani Mahsa ManafiBanimahdidehkordi ArmitaFekri MehrshadAsl Hossein BakhtarMoosavi MonaHeidari-Soureshjani Ehsan - Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor prognosis and presents considerable treatment challenges. However, the underlying molecular mechanisms remain incompletely understood. This study aimed to identify prognostic biomarkers through bioinformatics analysis and investigate the mechanisms governing proliferation and metastasis in MM. - Source: PubMed
Publication date: 2026/02/17
Fan HongjieWu YiwenPeng YuanyuanWang LingzhiTu ShengkePeng HuiYang JingLi XiaolanShi ZiweiLi MinSong Kui - Gaining insights into the molecular features associated with T cell exhaustion (TEX) can offer fresh perspectives on predicting treatment responses, and we aim to investigate TEX-related tumor associated macrophages (TAM) subset to deeply understand underlying mechanisms of immune exhaustion. - Source: PubMed
Publication date: 2025/12/22
Li ShanZhu JianjunHuang XiangJi FengmingLi JinrongYao ZhigangTang HaoyuLiu LingYan BingZhanghuang Chenghao - Head and neck cancer (HNC) continues to pose a significant global health challenge, highlighting the urgent need for discovering new therapeutic targets. Recent studies highlight the role of solute carrier (SLC) proteins in cancer progression. This study investigates the expression and potential role of SLC10A3 in HNC, aiming to determine its clinical significance and therapeutic relevance. Publicly available datasets, including The Cancer Genome Atlas (TCGA), Clinical Proteomics Tumor Analysis Consortium (CPTAC), and Gene Expression Omnibus (GEO), were analyzed to assess SLC10A3 expression in head and neck squamous cell carcinoma (HNSCC). The prognostic relevance of SLC10A3 was assessed using Kaplan-Meier (KM) survival and Receiver Operating Characteristic (ROC) curve analysis. Correlation analysis within TCGA, CPTAC, and GEO datasets identified genes associated with SLC10A3 expression. Protein-protein docking studies were performed to predict potential interactions between SLC10A3 and identified protein coding genes. SLC10A3 was found to be significantly upregulated in HNSCC tumor samples compared to normal tissues across TCGA and CPTAC datasets. Increased SLC10A3 expression correlated with poor survival outcomes in TCGA-HNSCC patients. Correlation analysis identified 26 genes positively associated with SLC10A3, where BCAP31, IRAK1, and UBL4A showed consistent correlation across TCGA, CPTAC, and GEO datasets. Computational protein interaction modeling using docking and AI/ML-based Evolutionary Scale Modelling (ESM) framework revealed significant binding affinities between SLC10A3 and identified protein-coding genes, suggesting potential functional interactions. These findings establish SLC10A3 as a promising therapeutic target in HNC. Its consistent upregulation, association with poor prognosis, and potential interactions with key regulatory proteins highlight its relevance for future therapeutic strategies. - Source: PubMed
Publication date: 2025/11/17
Bintee BinteeBanerjee RuchiraHegde MangalaManteghi NafisehBhuyan PlabitaLongkumar ImliwatiAhmed Gazi NaseemBaruah Munindra NarayanAhn Kwang SeokKunnumakkara Ajaikumar B - The predominant cause of cancer-related death worldwide is lung cancer. Poor survival rates are mainly due to late diagnosis due to the lack of sensitive and specific biomarkers and analytical tools. In this review, we examine the use of cancer-testis antigens (CTAs) as potential biomarkers due to their increased expression in malignancy. For example, the diagnostic potential of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) autoantibodies was low for sensitivity (48.3%) but higher for specificity (90.9%) in small cell lung cancer (SCLC). In contrast, A-kinase anchoring protein 4 (AKAP4) peripheral blood mononuclear cell (PBMC) quantitative polymerase chain reaction (qPCR) was 92.8% (sensitivity) and 92.6%, (specificity) in non-small cell lung cancer (NSCLC). We assess existing knowledge regarding CTAs and compare their effectiveness vs other markers such as NY-ESO-1, melanoma-associated antigen A (MAGE-A), sperm-associated antigen 9 (SPAG9), AKAP4, X antigen family member 1 (XAGE-1) and B-cell receptor-associated protein 31 (BCAP31). We also discuss the incorporation of CTA testing in lung cancer diagnostic workflows with focus on its analytical performance, preanalytical factors as well as comparative value vs existing markers. Finally, we outline the role of CTAs as companion diagnostics in immunotherapy and targeted treatment plans, and indicate the main challenges and research priorities towards the clinical translation of CTAs. - Source: PubMed
Publication date: 2025/10/30
Talele ChitraliAundhia ChintanTalele DipaliShah NiyatiKumari MamtaPandey Surya NathSingh NardevGupta GauravAl Shahwan MoayadDua Kamal